Preview

Diabetes mellitus

Advanced search

Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT-Т2DM)

https://doi.org/10.14341/DM9278

Abstract

Background: Cost-of-Illness Analysis (COI) constitutes the basis for the decision-making process on the budget and allocation in a modern health care system. Considering the wide prevalence of type 2 diabetes mellitus (Т2DM), it is important to perform COI in the Russian Federation (RF).


Aim: The aim of the secondary objective FORSIGHT-Т2DM study was to conduct Cost-of-Illness Analysis (COI) of Т2DM in the Russian Federation in relation to taking into consideration the presence of complications and concomitant diseases.


Materials and methods: COI of Т2DM was performed using the data obtained in Russian multicenter observational, pharmacoepidemiologic cross-sectional study of diabetes care for assessing routine healthcare pattern of T2DM in the Russian Federation (FORSIGHT-Т2DM). Information for each patient was collected from primary medical records and By asking patients to fill out a questionnaire. Total costs were calculated as the sum of direct medical costs (DCm), direct non-medical costs (DCn) and indirect costs (IC).


Results: The final analysis included data from 2014 patients with T2DM residing in 45 cities of RF. Total direct medical costs (DCm) of treating Т2DM and its complications and comorbidities amounted to 105 337 rubles ($2742) per patient per year; direct non-medical costs (DCn) amounted to 24 518 rubles ($638) per patient per year; indirect costs (IC) amounted to 149 754 rubles ($3898) per patient per year. The total cost of T2DM in RF in 2014 year amounted to 279 609 rubles ($7278) per patient. The total cost of T2DM in RF in 2014 amounted to 279 609 rubles per patient.


Conclusions: More than half (53,5%) of the total cost of T2DM is the loss of GDP due to patients’ disability. The DCm constitute 37,7% of the total cost of the disease, of which 57% is spent on treatment of T2DM complications and concomitant diseases, while only 10% is spent on glucose-lowering therapies.

About the Authors

Ivan I. Dedov

Endocrinology Research Centre


Russian Federation

MD, PhD, Professor



Marina F. Kalashnikova

Sechenov First Moscow State Medical University


Russian Federation

MD, PhD, Assistant professor of the Endocrinology chair



Dmitriy Y. Belousov

Center of Pharmacoeconomics and Outcomes Research


Russian Federation


Aleksey S. Kolbin

Pavlov First St. Petersburg State Medical University


Russian Federation

MD, PhD, Professor



Vladimir V. Rafalskiy

Smolensk State Medical University; Immanuel Kant Baltic Federal University


Russian Federation

MD, PhD, Professor



Aleksey E. Cheberda

Center of Pharmacoeconomics and Outcomes Research


Russian Federation


Mariya A. Kantemirova

City clinical hospital of S. P. Botkin


Russian Federation

MD



Vadim D. Zakiev

Sechenov First Moscow State Medical University


Russian Federation


Valentin V. Fadeyev

Sechenov First Moscow State Medical University


Russian Federation

MD, PhD, Professor



References

1. IDF Diabetes Atlas, 7th edition. Brussels: International Diabetes Federation; 2015. Available from: http://www.diabetesatlas.org.

2. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization; 2009. Available from: http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf

3. Дедов И.И., Шестакова М.В., Викулова О.К. Государственный регистр сахарного диабета в Российской Федерации: статус 2014 г. и перспективы развития // Сахарный диабет. – 2015. – Т. 18. – №3 – C. 5-22. [Dedov II, Shestakova MV, Vikulova OK. National register of diabetes mellitus in Russian Federation. Diabetes mellitus. 2015;18(3):5-22. (In Russ.)] doi: 10.14341/DM201535-22

4. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION) // Сахарный диабет. – 2016. – Т. 19. – № 2 – С. 104-112. [Dedov II, Shestakova MV, Galstyan GR. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus. 2016;19(2):104-112. (In Russ.)] doi: 10.14341/DM2004116-17

5. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta: US Dept of Health & Human Services, Centers for Disease Control and Prevention; 2017. Доступно: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf

6. Seuring T, Archangelidi O, Suhrcke M. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Pharmacoeconomics. 2015;33(8):811-831. doi: 10.1007/s40273-015-0268-9

7. Дедов И.И., Шестакова М.В., Сунцов Ю.И., и др. Результаты реализации подпрограммы «Сахарный диабет» Федеральной целевой программы «Предупреждение и борьба с социально значимыми заболеваниями 2007-2012 годы» // Сахарный диабет. – 2013. – Т. 16. – №2S. – C. 1-48. [Dedov II, Shestakova MV, Suntsov YI, et al. Federal targeted programme “Prevention and Management of Socially Significant Diseases (2007-2012)”: results of the “Diabetes mellitus” sub-programme. Diabetes mellitus. 2013;16(2S):1–48. (In Russ.)] doi: 10.14341/20720351-3879

8. Дедов И.И., Омельяновский В.В., Шестакова М.В., и др. Сахарный диабет как экономическая проблема в Российской Федерации // Сахарный диабет. – 2016. – Т. 19. – №1. – C. 30-43. [Dedov II, Omelyanovskiy VV, Shestakova MV, et al. Diabetes mellitus as an economic problem in Russian Federation. Diabetes mellitus. 2016;19(1):30-43. (In Russ.)] doi: 10.14341/DM7784

9. Дедов И.И., Калашникова М.Ф., Белоусов Д.Ю., и др. Фармакоэпидемиологические аспекты мониторинга здоровья пациентов с сахарным диабетом: результаты Российского наблюдательного многоцентрового исследования ФОРСАЙТ-СД 2 // Сахарный диабет. – 2016. – Т. 19. – №6. – С. 443-456. [Dedov II, Kalashnikova MF, Belousov DY, et al. Assessing routine healthcare pattern for type 2 diabetes mellitus in Russia: the results of рharmacoepidemiological study (FORSIGHT-DM2). Diabetes mellitus. 2016;19(6):443-456. (In Russ.)] doi: 10.14341/DM8146

10. Шамшурина Н.Г., Назаренко А.В., Шулятьев С.В. Сравнительный клинико-экономический анализ эффективности применения метода «кибернож» в онкологии // Здравоохранение. – 2015. – №7. – С. 42-51. [Shamshurina NG, Nazarenko AV, Shuljat’ev SV. Sravnitel’nyj kliniko-jekonomicheskij analiz jeffektivnosti primenenija metoda «kibernozh» v onkologii. Zdravoohranenie. 2015;(7):42-51. (In Russ.)]

11. Омельяновский В.В., Авксентьева М.В., Сура М.В., и др. Методические рекомендации по оценке влияния на бюджет в рамках реализации программы государственных гарантий бесплатного оказания гражданам медицинской помощи. Утверждены приказом ФГБУ «ЦЭККМП» Минздрава России от «23» декабря 2016 г. [Omel’janovskij VV, Avksent’eva MV, Sura MV, et al. Metodicheskie rekomendacii po ocenke vlijanija na bjudzhet v ramkah realizacii programmy gosudarstvennyh garantiĭ besplatnogo okazanija grazhdanam medicinskoĭ pomoshhi. Approved by order of Center for Healthcare Quality Assessment and Control 23 December 2016. (In Russ.)]

12. Guidelines for ATC classification and DDD assignment 2017. 20th edition. Oslo: WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health; 2016. Available from: https://www.whocc.no/filearchive/publications/2017_guidelines_web.pdf

13. Официальный сайт Департамента здравоохранения г. Москвы [интернет]. Перечень предельных оптовых и розничных цен на 26.12.2014. [Official site of the Moscow Healthcare Department [Internet]. The list of the maximum wholesale and retail prices as of December 26, 2014. (in Russ.)] Доступно по: http://mosgorzdrav.ru/ru-RU/citizens/health/drugs.html. Ссылка активна на 14.08.2017.

14. Информационный интернет-портал «Медицина для вас» [интернет]. Поиск лекарств в аптеках Москвы. [Information Internet portal «Medicine for you» [Internet]. Search for medicines in pharmacies in Moscow. (in Russ.)] Доступно по: http://www.medlux.ru. Ссылка активна на 14.08.2017

15. Постановление Правительства РФ от 18 октября 2013 г. N 932 «О программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2014 год и на плановый период 2015 и 2016 годов». [Order of the Gouvernment of Russian Federation on 18 October 2013. N932 “O programme gosudarstvennykh garantiy besplatnogo okazaniya grazhdanam meditsinskoy pomoshchi na 2014 god i na planovyy period 2015 i 2016 godov”. (In Russ.)] Доступно по: http://ivo.garant.ru/document?id=70379406&byPara=1. Ссылка активна на 14.08.2017.

16. Приказ Федерального фонда ОМС от 14 ноября 2013 г. N 229 «Об утверждении «Методических рекомендаций по способам оплаты специализированной медицинской помощи в стационарных условиях и в дневных стационарах на основе групп заболеваний, в том числе клинико-статистических групп (КСГ) и клинико-профильных групп (КПГ) за счет средств системы обязательного медицинского страхования». [Order of the Federal Obligatory Medical Insurance Fund on 14 November 2013. N229 “Ob utverzhdenii “Metodicheskikh rekomendatsiy po sposobam oplaty spetsializirovannoy meditsinskoy pomoshchi v statsionarnykh usloviyakh i v dnevnykh statsionarakh na osnove grupp zabolevaniy, v tom chisle klinikostatisticheskikh grupp (KSG) i kliniko-profil’nykh grupp (KPG) za schet sredstv sistemy obyazatel’nogo meditsinskogo strakhovaniya”. (In Russ.)] Доступно по: http://ivo.garant.ru/document?id=70418710&byPara=1. Ссылка активна на 14.08.2017.

17. Progavrichenko.ru [интернет]. Размер социальной пенсии по инвалидности в 2014 году. [Progavrichenko.ru [Internet]. The size of the social disability pension in 2014. (In Russ.)] Доступно по: http://progavrichenko.ru/lgoty-posobiya-pensii/razmer-pensij-po-invalidnosti-v-2014-godu.html. Ссылка активна на 14.08.2017.

18. Федеральный закон Российской Федерации №173-ФЗ от 17 декабря 2001 «О трудовых пенсиях в Российской Федерации (ред. от 03.12.2012)». [Federal Law of Russian Federation N173-FZ on 17 December 2001. «O trudovyh pensijah v Rossijskoj Federacii (ed on 03.12.2012)». (In Russ.)] Доступно по: http://www.consultant.ru/document/cons_doc_LAW_34443. Ссылка активна на 14.08.2017.

19. Федеральная служба государственной статистики [Интернет]. Среднемесячная номинальная начисленная заработная плата работников в целом по экономике Российской Федерации в 1991-2017 гг. [Russian Federal State Statistics Service [Internet]. Average monthly nominal accrued wages of workers in the whole of the economy of the Russian Federation in 1991-2017. (in Russ.)] Доступно по: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/wages/. Cсылка активна на 01.06.2017 г.

20. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381. doi: 10.1093/eurheartj/ehw106

21. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. – 8-й выпуск // Сахарный диабет. – 2017. – Т. 20. – №1S. – C. 1-121.[Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition. Diabetes mellitus. 2017;20(1S):1-121. (In Russ.)] doi: 10.14341/DM8146

22. Консультант Плюс [интернет]. Курс доллара и евро в 2014 году. [Consultant Plus [Internet]. The USD and the Euro in 2014. (in Russ.)] Доступно по: https://www.consultant.ru/law/ref/stavki/kurs-dollar-euro/ Ссылка активна на 01.06.2017 г.

23. Ng CS, Lee JY, Toh MP, Ko Y. Cost-of-illness studies of diabetes mellitus: A systematic review. Diabetes Res Clin Pract. 2014;105(2):151-163. doi: 10.1016/j.diabres.2014.03.020

24. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033-1046. doi: 10.2337/dc12-2625

25. Дедов И.И., Концевая А.В., Шестакова М.В., и др. Экономические затраты на сахарный диабет 2 типа и его основные сердечно-сосудистые осложнения в Российской Федерации // Сахарный диабет. – 2016. – Т. 19. – №6. – C. 518-527. [Dedov II, Kontsevaya AV, Shestakova MV, et al. Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation. Diabetes mellitus. 2016;19(6):518-527. (In Russ.)] doi: 10.14341/DM8153

26. Bruno G, Picariello R, Petrelli A, et al. Direct costs in diabetic and non diabetic people: the population-based Turin study, Italy. Nutr Metab Cardiovasc Dis. 2012;22(8):684–690. doi: 10.1016/j.numecd.2011.04.007

27. Kim TH, Chun KH, Kim HJ, et al. Direct medical costs for patients with type 2 diabetes and related complications: a prospective cohort study based on the korean national diabetes program. J Korean Med Sci. 2012;27(8):876-882. doi: 10.3346/jkms.2012.27.8.876

28. Ulrich S, Holle R, Wacker M, et al. Cost burden of type 2 diabetes in Germany: results from the population-based KORA studies. BMJ Open. 2016;6(11):e012527. doi: 10.1136/ bmjopen-2016-012527

29. Mata-Cases M, Casajuana M, Franch-Nadal J, et al. Direct medical costs attributable to type 2 diabetes mellitus: a population-based study in Catalonia, Spain. Eur J Health Econ. 2016;17(8):1001-1010. doi: 10.1007/s10198-015-0742-5

30. Porath A, Fund N, Maor Y. Costs of managing patients with diabetes in a large health maintenance organization in Israel: a retrospective cohort study. Diabetes Ther. 2017;8(1):167-176. doi: 10.1007/s13300-016-0212-9

31. Williams R, Van Gaal L, Lucioni C; CODE-2 Advisory Board. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia. 2002;45(7):13-17. doi: 10.1007/s00125-002-0859-9

32. Hex N, Bartlett C, Wright D, et al. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855–862. doi: 10.1111/j.1464-5491.2012.03698.x

33. Marcellusi A, Viti R, Mecozzi A, Mennini FS. The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach. Eur J Health Econ. 2016;17(2):139–147. doi: 10.1007/s10198-014-0660-y

34. Javanbakht M, Baradaran HR, Mashayekhi A, et al. Cost-of-illness analysis of type 2 diabetes mellitus in Iran. PLoS ONE. 2011;6(10):e26864. doi: 10.1371/journal.pone.0026864.


Supplementary files

1. SUPPLEMENT 1. Therapeutic profile of consumption of oral and non-insulin hypoglycemic drugs in non-monetary and in money terms.
Subject
Type Исследовательские инструменты
Download (56KB)    
Indexing metadata ▾
2. SUPPLEMENT 2. The insulin consumption structure and pharmacotherapy cost in non-monetary and monetary terms.
Subject
Type Исследовательские инструменты
Download (48KB)    
Indexing metadata ▾
3. SUPPLEMENT 3. The antihypertensive drugs consumption structure and their cost in non-monetary and monetary terms.
Subject
Type Исследовательские инструменты
Download (46KB)    
Indexing metadata ▾
4. SUPPLEMENT 4. The lipid-lowering drugs consumption structure and their cost per patient per year in non-monetary and monetary terms.
Subject
Type Исследовательские инструменты
Download (34KB)    
Indexing metadata ▾
5. Fig. 1. Prevalence of complications and concomitant diseases among patients with type 2 diabetes in the FORSIGHT-SD2 study [9].
Subject
Type Исследовательские инструменты
View (158KB)    
Indexing metadata ▾
6. Fig. 2. The structure of direct medical costs for type 2 diabetes mellitus in Russia based on the results of the FORSIGHT-SD2 study.
Subject
Type Исследовательские инструменты
View (105KB)    
Indexing metadata ▾
7. Fig. 3. The structure of costs for glucose-lowering therapy in Russia based on the results of the FORSIGHT-SD2 study.
Subject
Type Исследовательские инструменты
View (112KB)    
Indexing metadata ▾

Review

For citations:


Dedov I.I., Kalashnikova M.F., Belousov D.Y., Kolbin A.S., Rafalskiy V.V., Cheberda A.E., Kantemirova M.A., Zakiev V.D., Fadeyev V.V. Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT-Т2DM). Diabetes mellitus. 2017;20(6):403-419. (In Russ.) https://doi.org/10.14341/DM9278

Views: 3605


ISSN 2072-0351 (Print)
ISSN 2072-0378 (Online)